RAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ralliant Corp (RAL) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has recently faced significant challenges, including a $1.4 billion goodwill impairment, weak financial performance, and a downward revision in price targets by multiple analysts. While there are some positive signals like insider confidence and a slight revenue increase, the overall sentiment and financial outlook are not favorable for long-term investment at this time.
The technical indicators are mixed. The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The stock is trading near its resistance level (R1: 46.439), which could limit upside potential in the short term.
Insider buying activity in the Invesco S&P Spin-Off ETF suggests management confidence. Additionally, the MACD indicator shows positive momentum, and the stock is trading near its support levels.
The company reported a $1.4 billion goodwill impairment, leading to a 31.8% stock price drop. Multiple analysts have downgraded their price targets, citing weaker-than-expected guidance and increased operating costs. Investigations by law firms into potential securities violations further dampen investor confidence.
In Q4 2025, revenue increased by 1.19% YoY to $554.6 million. However, net income dropped significantly to -$1.37 billion (-1761.31% YoY), and EPS fell to -12.17 (-1767.12% YoY). Gross margin also declined slightly to 50.49%. The financial performance indicates severe challenges, particularly with profitability.
Analysts have mixed views but lean negative. Recent ratings include multiple price target reductions, with targets ranging from $41 to $52. While some analysts maintain Buy or Overweight ratings, the consensus reflects concerns about the company's outlook and financial health.
